| Aug 3 |
Zevra wins FDA AdCom backing for rare disease therapy arimoclomol
|
| Aug 2 |
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
|
| Jul 31 |
Zevra stock climbs 16% ahead of FDA meeting on arimoclomol
|
| Jul 30 |
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
|
| Jul 18 |
Insiders Buying Zevra Therapeutics And 1 Other Stock
|
| Jul 17 |
Insiders Buying Barnes & Noble Education And 2 Other Stocks
|
| Jul 16 |
Zevra Therapeutics rises as director buys $60K in company shares
|
| Jul 12 |
Zevra Therapeutics Insider Confidence Rewarded, Stock Hits US$235m Market Cap
|
| Jul 10 |
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
|
| Jul 10 |
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
|
